Antitumor agent-88 

Antitumor agent-88 exhibits potent antimitotic activity and arrests cell in the G2/M phase. Antitumor agent-88 disrupts the microtubule and the cytoskeleton in CYP1A1-expressing breast cancer cells. Antitumor agent-88 is also a competitive inhibitor of CYP1A1 (K_i: 1.4 μM)^[1].

Antitumor agent-88 (Compound 14, 48 h) inhibits MCF-7 cell growth, with an IC₅₀ of 200 nM, and is inactive on MDA-MB-231 (IC₅₀ >8600 nM)^[1].
Antitumor agent-88 inhibits MDA-MB-468, SK-BR cell growth with IC₅₀s of 21 nM, 3.2 nM^[1].
Antitumor agent-88 (50 nM, 48 h) causes accumulation of the cells in the G2/M phase by 42%^[1].
Antitumor agent-88 shows high affinity for CYP1A1 (K_i: 1.4 μM)^[1].
Antitumor agent-88 selectively inhibits HT-1080 cell proliferation, with IC₅₀s of 30 nM for HT-1080 transfected withCYP1A1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Antitumor agent-88 (Compound 14) (1 μg/egg) shows antitumoral activities in the chick embryos bearing HT-1080CYP1A1 tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

478.56

C₂₃H₃₀N₂O₇S

1422527-87-4

CCCCCN1CCN(C2=CC=C(S(=O)(OC3=CC(OC)=C(C(OC)=C3)OC)=O)C=C2)C1=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chavez Alvarez AC, et al. Homologation of the Alkyl Side Chain of Antimitotic Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonate Prodrugs Selectively Targeting CYP1A1-Expressing Breast Cancers Improves Their Stability in Rodent Liver Microsomes. J Med Chem. 2023 Feb 23;66(4):2477-2497.  [Content Brief]